Datasets:
SMILES stringlengths 71 300 | POI_Name stringclasses 164
values | POI_Sequence stringclasses 133
values | Ligase_Name stringclasses 9
values | Cell_Line stringclasses 155
values | Value_Type stringclasses 2
values | Value_Unit stringclasses 2
values | Value float64 -53.5 100k | Value_Error float64 1 81.3 ⌀ | Value_Range_Min float64 0.1 1.49k ⌀ | Value_Range_Max float64 0.76 1.99k ⌀ | Value_Concentration float64 0.1 100 ⌀ | Assay_Time float64 2 96 ⌀ | Value_Operator stringclasses 5
values | Value_Category stringclasses 2
values | Value_Concentration_Unit stringclasses 2
values | Modality stringclasses 1
value | POI_UniProt stringclasses 131
values | Ligase_UniProt stringclasses 11
values | Ligase_Sequence stringclasses 11
values | Cell_Line_ID stringclasses 154
values | Cell_Line_Species stringclasses 4
values | Reference stringclasses 367
values | Description stringclasses 501
values | Database stringclasses 6
values | Assay stringclasses 21
values | TPD_ID stringlengths 10 10 ⌀ | Cell_Line_Description stringclasses 151
values | POI_Cluster int64 -1 37 | SMILES_Held_Out bool 2
classes | SMILES_Scaffold_Cluster int64 -1 2.35k | SMILES_Butina_Cluster int64 -1 278 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
C#Cc1c(F)ccc2cc(O)cc(-c3nc(O)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-6RLL4D | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(O)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 10 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-6RLL4D | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-R97O5I | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 1 | 222 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-R97O5I | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 1 | 222 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-OMKS0Z | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-OMKS0Z | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-V7I2WM | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-V7I2WM | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)C6CCC7(CC6)CN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 21 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-BJDZ82 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 2 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)CC6CC7(C6)CN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 52 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-XJ3ZX9 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 3 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCc6ccc(-c7scnc7C)cc6)C(C)(C)C)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 54 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-F4M7CY | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 4 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)Cc6ccc(OCCC(=O)N[C@H](C(=O)N7C[C@H](O)C[C@H]7C(=O)NCc7ccc(-c8scnc8C)cc7)C(C)(C)C)nc6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 51 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-GVUFF9 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 5 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CC(C#Cc7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)C6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-7XE4D9 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 6 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CC(C#Cc7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)C6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-7XE4D9 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 6 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CC7(CCN(c8ccc(C(=O)N[C@H](C(=O)N9C[C@H](O)C[C@H]9C(=O)N[C@@H](C)c9ccc(-c%10scnc%10C)cc9)C(C)(C)C)cc8)CC7)C6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 72 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-79X3KH | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 7 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-O9G3ZB | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 8 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-O9G3ZB | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 8 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(CN7CCC(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-HEM71P | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 9 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(CN7CCC(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-HEM71P | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 9 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(CN7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-CB461N | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 10 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(CN7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-CB461N | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 10 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(COc7ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)cc7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 24 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-WPMMAJ | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 11 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(Cc7ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)cc7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 55 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-R66TBE | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 12 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(N7CCC(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-Q0GL7U | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 13 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(N7CCC(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-Q0GL7U | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 13 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC7(CC6)CCN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)CC7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 29 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-1EL1DC | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 14 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC7(CC6)CN(Oc6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 40 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-H5YY14 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 15 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC7(CC6)CN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 20 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-7ZHOU5 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 16 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC7(CC6)CN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cn6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 24 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-Y988UK | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 17 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-AKAEQ5 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 18 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-AKAEQ5 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 18 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC#Cc7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-QTS3OL | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 19 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC#Cc7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-QTS3OL | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 19 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(=O)n(C%10CCC(=O)NC%10=O)ncc9c8)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-Z06K1K | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 20 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(=O)n(C%10CCC(=O)NC%10=O)ncc9c8)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-Z06K1K | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 20 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-E6B6YH | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-E6B6YH | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)C7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-7KZ6LE | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 21 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)C7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-7KZ6LE | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 21 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-PPJMKT | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-PPJMKT | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)CC)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-T6TCFY | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)CC)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 10 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-T6TCFY | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C#Cc1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCN(CC)CCOc2ccc(C(=O)c3c(-c4ccc(O)cc4)sc4cc(O)ccc34)cc2)C(C)(C)C)cc1 | ESR1 | MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAYEFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPFLQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALL... | VHL | MCF-7 | Dmax | % | 10 | null | null | null | null | 4 | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P03372 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0031 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/30990042/ | EC50 of ligand was measured in MCF7 cells. DCmax was measured in 1 nM (at 10 nM 76 %). | PROTACpedia | null | null | African=0.74%; Native American=0%; East Asian, North=4.2%; East Asian, South=0%; South Asian=0%; European, North=56.91%; European, South=38.15%.
Helen Marion Mallon (sister Catherine Frances), the patient from which this cell line is derived was a nun at the Immaculate Heart of Mary convent in Monroe, Michigan (CelloPu... | 15 | false | 22 | 0 |
C#Cc1ccc([C@H](CC(=O)N2CCC(C#Cc3ccc(C(=O)N[C@H]4C(C)(C)[C@H](Oc5ccc(C#N)c(Cl)c5)C4(C)C)cc3)CC2)NC(=O)[C@H]2C[C@H](O)CN2C(=O)[C@@H](c2cc(C)no2)C(C)C)cc1 | AR | MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGL... | VHL | LNCaP | Dmax | % | 99 | null | null | null | null | 6 | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P10275 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0395 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/31804827/ | null | PROTACpedia | null | null | Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01
Instable (MSI).
Metastatic; Left supraclavicular lymph node;
Caucasian.
Space-flown cell line (cellonaut).
Cancer cell line | 16 | false | 23 | 70 |
C#Cc1ccc([C@H](CC(=O)N2CCC(N3CCC(C#Cc4ccc(C(=O)N[C@H]5C(C)(C)[C@H](Oc6ccc(C#N)c(Cl)c6)C5(C)C)cc4)CC3)CC2)NC(=O)[C@H]2C[C@H](O)CN2C(=O)[C@@H](c2cc(C)no2)C(C)C)cc1 | AR | MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGL... | VHL | LNCaP | Dmax | % | 99 | null | null | null | null | 6 | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P10275 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0395 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/31804827/ | null | PROTACpedia | null | null | Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01
Instable (MSI).
Metastatic; Left supraclavicular lymph node;
Caucasian.
Space-flown cell line (cellonaut).
Cancer cell line | 16 | false | 24 | 0 |
C#Cc1cccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-FWIBTM | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1cccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-FWIBTM | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)CC6CCN(c7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-GQ7KAX | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 25 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)CC6CCN(c7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-GQ7KAX | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 25 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(C(=O)N7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-ZB5KH5 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 26 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(C(=O)N7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-ZB5KH5 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 26 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(CC(=O)N[C@@H](C(=O)N8C[C@@H](O)C[C@@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-AI4FTL | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 27 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(CC(=O)N[C@@H](C(=O)N8C[C@@H](O)C[C@@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-AI4FTL | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 27 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(CCC(=O)N[C@@H](C(=O)N8C[C@@H](O)C[C@@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-PQVQUK | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 28 | 0 |
TACK — TArgeting Chimeras Knowledge
A curated, ML-ready dataset and benchmark for PROTAC degradation activity prediction
Overview
Proteolysis-targeting chimeras (PROTACs) are a promising drug modality that induces targeted protein degradation by hijacking the cell's native ubiquitin–proteasome system. However, rational PROTAC design remains challenging due to the complex interplay between molecular structure, target proteins (POIs), E3 ligases, and cellular context.
TACK addresses three critical gaps in existing PROTAC ML benchmarks:
- Data scarcity and inconsistency — harmonized from three major public repositories with standardized SMILES, protein annotations, and experimental conditions
- Lack of rigorous benchmarks — scaffold-based 5×5 cross-validation and formal statistical testing (Friedman, Wilcoxon, Tukey HSD) rather than simple train/test splits
- Limited scope — supports regression (pDC₅₀, Dmax) and binary classification, not just the binary classification framing common in prior work
Ribes*, Dunlop*, and Mercado. TACK: A statistical evaluation of degradation activity on a novel TArgeting Chimeras Knowledge dataset. KDD AI for Sciences Track, 2026.
Dataset at a Glance
| Statistic | TPDdb | PROTAC-DB | PROTACpedia | TACK |
|---|---|---|---|---|
| Total records | 22,183 | 9,380 | 1,203 | 6,561 |
| Unique PROTACs | 21,429 | 6,110 | 1,189 | 3,514 |
| Degradation endpoints | 6,518 | 2,170 | 580 | 6,561 |
| POI targets | 184 | 441 | 79 | 164 |
| E3 ligases | 8 | 21 | 8 | 9 |
| Cell lines | 142 | — | 139 | 155 |
| Hold-out set entries | — | — | — | 913 |
The dataset contains 4,184 DC₅₀ and 2,377 Dmax measurements. Approximately 55% of entries are classified as active (DC₅₀ ≤ 100 nM and Dmax ≥ 80%).
Most represented biology:
- POIs: Androgen Receptor (26.7%), SMARCA2 (12.0%), BTK (8.9%) — top 5 account for 61.6% of endpoints
- E3 ligases: CRBN and VHL together account for 98.7% of measurements
- Cell lines: LNCaP (20.9%), SW1573 (15.2%), Mino (7.0%) across 155 unique lines
Configs (Subsets)
| Config | Description | Examples |
|---|---|---|
default |
All endpoints (DC₅₀ + Dmax combined) | 6,561 |
DC50 |
Potency measurements only | 4,184 |
Dmax |
Maximal degradation efficacy only | 2,377 |
multitask |
Paired DC₅₀ + Dmax for the same PROTAC/assay, also used for binary activity classification | 1,563 |
Loading the Dataset
from datasets import load_dataset
# All endpoints
ds = load_dataset("ailab-bio/TACK")
# DC50 only
ds_dc50 = load_dataset("ailab-bio/TACK", "DC50")
# Dmax only
ds_dmax = load_dataset("ailab-bio/TACK", "Dmax")
# Paired multitask (DC50 + Dmax for same compound)
ds_multi = load_dataset("ailab-bio/TACK", "multitask")
The SMILES_Held_Out column flags the structurally dissimilar held-out set (~10% of data). To reproduce the train/validation split used in the paper:
ds = load_dataset("ailab-bio/TACK", "DC50")["train"]
train_val = ds.filter(lambda x: not x["SMILES_Held_Out"])
held_out = ds.filter(lambda x: x["SMILES_Held_Out"])
Schema
Common columns (all configs)
| Column | Type | Description |
|---|---|---|
SMILES |
string | Canonical RDKit SMILES of the PROTAC |
POI_Name |
string | Gene name of the protein of interest |
POI_Sequence |
string | UniProt amino acid sequence of the POI |
POI_UniProt |
string | UniProt accession for the POI |
Ligase_Name |
string | Name of the E3 ligase |
Ligase_Sequence |
string | UniProt amino acid sequence of the E3 ligase |
Ligase_UniProt |
string | UniProt accession for the E3 ligase |
Cell_Line |
string | Cell line name (Cellosaurus-standardized) |
Cell_Line_ID |
string | Cellosaurus identifier |
Cell_Line_Species |
string | Species of origin for the cell line |
Cell_Line_Description |
string | Textual description from Cellosaurus |
Value |
float64 | Measured endpoint value |
Value_Unit |
string | Unit of the value (nM for DC₅₀; % for Dmax) |
Value_Type |
string | Endpoint type (DC50 or Dmax) |
Value_Operator |
string | Comparison operator if censored (<, >, etc.) |
Value_Error |
float64 | Reported measurement error (if available) |
Value_Range_Min |
float64 | Lower bound for range-reported values |
Value_Range_Max |
float64 | Upper bound for range-reported values |
Value_Concentration |
float64 | Treatment concentration for Dmax assays |
Value_Concentration_Unit |
string | Unit of treatment concentration |
Value_Category |
string | Categorical activity label (where applicable) |
Assay_Time |
float64 | Treatment duration in hours |
Assay |
string | Standardized assay type (e.g., Western Blot, HiBit) |
Modality |
string | Compound modality (PROTAC, molecular glue, etc.) |
Reference |
string | Source literature or patent reference |
Description |
string | Original assay description |
Database |
string | Source database (TPDdb, PROTAC-DB, PROTACpedia) |
TPD_ID |
string | Original identifier in the source database |
POI_Cluster |
int64 | POI sequence-based cluster ID |
SMILES_Scaffold_Cluster |
int64 | Murcko scaffold cluster ID (used for CV splitting) |
SMILES_Butina_Cluster |
int64 | Butina/Tanimoto cluster ID |
SMILES_Held_Out |
bool | True if this entry belongs to the structural hold-out set |
The multitask config replaces Value, Value_Unit, etc. with Value_DC50, Value_Dmax and analogous suffixed columns, enabling simultaneous supervision on both endpoints.
Curation Pipeline
Raw data was aggregated from three repositories and cleaned through a multi-stage pipeline:
- SMILES standardization — canonicalization via RDKit; duplicates resolved by weighted scoring
- Endpoint standardization — DC₅₀ values converted to nM; range values converted to arithmetic mean with bounds stored; censored values (operators) preserved but flagged for exclusion from evaluation sets; categorical patent grades excluded
- Protein annotation — POI and E3 ligase names mapped to UniProt accessions; amino acid sequences retrieved from UniProt; BRD4 isoform handling applied
- Cell line standardization — validated against Cellosaurus; standardized identifiers and descriptions attached
- Assay standardization — assay descriptions parsed and normalized (e.g., "WB" → "Western Blot"); treatment concentrations extracted from metadata and free-text fields
- Hold-out construction — ~10% most structurally dissimilar PROTACs (by average Tanimoto distance using 512-bit Morgan8 fingerprints) isolated before any model training
- Scaffold-based CV clustering — remaining data grouped by Murcko scaffolds to prevent leakage between CV folds
Please refer to this link for the codebase used to generate the data.
Benchmark Results
Models were evaluated using scaffold-based 5×5 repeated cross-validation with statistical testing (Friedman + Wilcoxon + Benjamini–Hochberg correction for feature selection; Tukey HSD for architecture comparison).
Regression (hold-out set)
| Task | Model | MAE | RMSE | R² | Spearman ρ |
|---|---|---|---|---|---|
| pDC₅₀ | MLP | 0.58 | 0.80 | 0.66 | 0.76 |
| Dmax | XGBoost | 18.86 | 25.68 | 0.36 | 0.66 |
Binary Classification (validation folds, mean ± CI)
| Model | ROC-AUC | PR-AUC | MCC | Recall @ Prec≥0.8 |
|---|---|---|---|---|
| XGBoost | 0.851 | 0.870 | 0.523 | 0.777 |
| MLP | 0.799 | 0.824 | 0.448 | 0.600 |
| PROTAC-STAN | 0.746 | 0.773 | 0.405 | 0.443 |
All pairwise differences are statistically significant (Tukey HSD, p < 0.001).
Key findings:
- pDC₅₀ is substantially more predictable than Dmax (R² 0.66 vs. 0.36), reflecting the greater dependence of maximal degradation on cellular factors not captured by current molecular representations
- Classical tree-based methods (XGBoost) outperform the domain-specific GNN PROTAC-STAN, consistent with the small-to-medium tabular dataset regime
- Simple one-hot or n-gram protein encodings often match expensive ESM-S embeddings, particularly with XGBoost; ESM-S embeddings give a modest advantage for XGBoost on the classification task
Ensemble Uncertainty Quantification
Ensemble standard deviation correlates positively with absolute prediction error, enabling confidence-aware compound prioritization:
| Task | Method | RMSE | Spearman ρ (σ vs. |error|) |
|---|---|---|---|
| pDC₅₀ | Caruana (33 models) | 0.672 | 0.207* |
| pDC₅₀ | Uniform avg (500 models) | 0.683 | 0.355** |
| Dmax | Caruana (22 models) | 21.32 | 0.543** |
| Dmax | Uniform avg (500 models) | 22.92 | 0.694** |
** p < 0.001; * p < 0.01
Best Models
Pre-trained ensemble models (XGBoost and MLP, all feature configurations, 25 CV folds each) are available on Zenodo:
Citation
If you use TACK in your research, please cite:
@misc{ribes2026tackstatisticalevaluationdegradation,
title={TACK: A statistical evaluation of degradation activity on a novel TArgeting Chimeras Knowledge dataset},
author={Stefano Ribes and Nils Dunlop and Rocío Mercado},
year={2026},
eprint={2605.19579},
archivePrefix={arXiv},
primaryClass={q-bio.QM},
url={https://arxiv.org/abs/2605.19579},
}
License
The TACK dataset is released under the MIT License. The underlying experimental data is sourced from PROTAC-DB, PROTACpedia, and TPDdb — please refer to the respective database licenses for conditions on downstream use of the original data.
Acknowledgements
SR and RM acknowledge funding from the Chalmers Gender Initiative for Excellence (Genie). RM and ND acknowledge funding from the Wallenberg AI, Autonomous Systems and Software Program (WASP), supported by the Knut and Alice Wallenberg Foundation. The authors thank Yossra Gharbi, Alexander Persson, and Felix Erngård for helpful discussions. Computations were enabled by Chalmers e-Commons and NAISS (grant 2022-06725).
- Downloads last month
- 188